fbpx

BioPorto – Presentation of interim report 2022

BioPorto - Presentation of interim report 2022 17 AugustAug 2022 14:00 - 14:30Online Event

BioPorto – Presentation of interim report 2022

BioPorto releases its Interim Report for the second quarter of 2022 on August 17th and participates in a digital event hosted by HC Andersen Capital on August 17th at 2 pm CET. CEO Tony Pare and CFO Neil Goldman will present the report and highlights from the half-year period, followed by a moderated Q&A session.

On June 28th BioPorto announced that it completed the targeted enrollment of 600 patients for the clinical study of The NGAL Test. After the data from the study is collected, compiled and analyzed and other required technical and analytical documentation are finalized, the company expects to submit it to the US FDA for approval in patients aged 3 months up to 22 years. By assessing the risk of Acute Kidney Injury (AKI) much faster than current methods, the NGAL test can save lives.

Disclaimer: HC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate Visibility agreement.

Deltag her

Du vil blive videresendt til en ekstern tilmeldingsside. 

Information

BioPorto - Presentation of interim report 2022 17 AugustAug 2022 14:00 - 14:30
BioPorto - Presentation of interim report 2022 Online Event
Bioporto
BioPorto - Presentation of interim report 2022 17 AugustAug 2022 14:00 - 14:30Online Event

BioPorto – Presentation of interim report 2022

BioPorto releases its Interim Report for the second quarter of 2022 on August 17th and participates in a digital event hosted by HC Andersen Capital on August 17th at 2 pm CET. CEO Tony Pare and CFO Neil Goldman will present the report and highlights from the half-year period, followed by a moderated Q&A session.

On June 28th BioPorto announced that it completed the targeted enrollment of 600 patients for the clinical study of The NGAL Test. After the data from the study is collected, compiled and analyzed and other required technical and analytical documentation are finalized, the company expects to submit it to the US FDA for approval in patients aged 3 months up to 22 years. By assessing the risk of Acute Kidney Injury (AKI) much faster than current methods, the NGAL test can save lives.

Disclaimer: HC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate Visibility agreement.

Information

BioPorto - Presentation of interim report 2022 17 AugustAug 2022 14:00 - 14:30
BioPorto - Presentation of interim report 2022 Online Event
Bioporto